<DOC>
	<DOC>NCT00929539</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.</brief_summary>
	<brief_title>Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Have type 2 diabetes; 2. Body mass index (BMI) of &gt; 27.0 kg/m2 and ≤ 45.0 kg/m2; 3. Are either drug naïve with respect to hypoglycemic agents OR are currently being treated with metformin alone or in combination with a sulfonylurea. Metformin and sulfonylurea dosing must be stable. 1. Females who are pregnant or breastfeeding 2. Known medical history or presence of type 1 diabetes, pancreatitis, unstable or rapidly progressing retinopathy, nephropathy or neuropathy; 3. Acute coronary syndrome or uncontrolled hypertension; 4. Does not meet medication restriction criteria, as described in the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>